Loading
Pharmaceutical
6 min read
Areas of Expertise :
Pharmaceutical, Toxicology, Epidemiology, Pharmacology, Product Liability
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Eleventh Circuit
The ranitidine litigation, commonly referred to as the Zantac NDMA cases, represents one of the most closely examined pharmaceutical toxic tort disputes in modern U.S. mass tort practice. The litigation emerged after independent laboratory testing reported that ranitidine, the active ingredient in Zantac, could chemically degrade to form N-nitroso dimethylamine (NDMA), a nitrosamine compound treated within regulatory and toxicological frameworks as a probable human carcinogen.
Plaintiffs alleged that long-term ranitidine use resulted in cumulative NDMA exposure at levels capable of increasing cancer risk. The asserted injuries most commonly included bladder, gastric (stomach), pancreatic, esophageal, liver, and colorectal cancers, although the specific cancers evaluated varied by jurisdiction and procedural posture. From a legal standpoint, the litigation became a focal point for evaluating product ingredient toxicity theories, pharmaceutical stability allegations, and the evidentiary standards governing toxicology-based general causation under Daubert-style gatekeeping frameworks.
Although many claims did not survive general causation challenges, the litigation remains significant for its detailed judicial treatment of toxicological proof, expert methodology, and the limits of regulatory action in establishing civil liability.
In 2019, independent laboratory testing reported that ranitidine could form NDMA under certain conditions, including storage over time and exposure to elevated temperatures. These findings raised questions regarding the inherent chemical stability of the ranitidine molecule and prompted regulatory scrutiny in the United States and internationally. From a litigation perspective, the testing framed the dispute as involving potential degradation of an active pharmaceutical ingredient rather than isolated manufacturing contamination.
During this period, the U.S. Food and Drug Administration publicly acknowledged the testing data and initiated its own evaluation of NDMA levels in ranitidine products, setting the stage for subsequent regulatory and civil developments.
In April 2020, the FDA requested the withdrawal of all prescription and over-the-counter ranitidine products from the U.S. market. The agency cited data indicating that NDMA levels in some ranitidine products could increase over time and potentially exceed acceptable daily intake limits under certain storage conditions.
The FDA emphasized that its action was precautionary and did not include findings regarding cancer causation. Nonetheless, the withdrawal influenced subsequent civil litigation by reinforcing concerns related to product chemistry, pharmaceutical stability, and potential toxicological risk.
Following the FDA’s withdrawal request, thousands of personal injury lawsuits were filed nationwide. Federal cases were centralized into multidistrict litigation in the Southern District of Florida, where the court coordinated pretrial proceedings and addressed common scientific and evidentiary issues. Parallel proceedings advanced in multiple state courts, with plaintiffs asserting toxic tort theories centered on ranitidine’s alleged chemical instability, NDMA exposure pathways, and claimed links to cancer development. Across jurisdictions, toxicology, pharmacology, chemistry, and epidemiology became central to the evidentiary record, with general causation emerging as a threshold issue.
In late 2022, the federal MDL court excluded plaintiffs’ general causation expert testimony under Daubert. The court concluded that the proposed methodologies failed to reliably connect laboratory testing, regulatory thresholds, and epidemiological data to real-world human exposure capable of causing cancer.
Summary judgment was entered in favor of defendants for the designated cancer claims addressed by the court. The rulings focused on evidentiary sufficiency and did not purport to resolve causation for every cancer type alleged across all jurisdictions.
In September 2022, a large volume of ranitidine cases was filed in Delaware Superior Court. Plaintiffs designated ten general causation experts across multiple cancer types, while defendants designated a single general causation expert.
In May 2024, the Delaware Superior Court denied defendants’ motions to exclude plaintiffs’ experts under Rule 702. In July 2025, the Delaware Supreme Court reversed, concluding that plaintiffs’ general causation evidence failed to provide a scientifically reliable bridge between NDMA hazard data, laboratory testing, and ranitidine-specific human exposure. The matter was remanded for proceedings consistent with exclusion of general causation testimony.
Despite adverse general causation rulings, a number of state-court claims were resolved through negotiated settlements beginning in 2024. Several manufacturers announced settlement frameworks resolving substantial volumes of claims without admissions of liability.
These resolutions reflected litigation risk management, jurisdictional uncertainty, and cost considerations rather than judicial findings establishing scientific causation.
Court:
United States District Court for the Southern District of Florida
Case Name:
In re Zantac (Ranitidine) Products Liability Litigation
Pharmaceutical Product Liability
Carcinogenesis
Chemical Exposures
Chemical Analysis
Drug Regulation
FDA Regulation
Risk Assessment
Product Safety
The ranitidine litigation, commonly referred to as the Zantac NDMA cases, represents one of the most closely examined pharmaceutical toxic tort disputes in modern U.S. mass tort practice. The litigation emerged after independent laboratory testing reported that ranitidine, the active ingredient in Zantac, could chemically degrade to form N-nitroso dimethylamine (NDMA), a nitrosamine compound treated within regulatory and toxicological frameworks as a probable human carcinogen.
Plaintiffs alleged that long-term ranitidine use resulted in cumulative NDMA exposure at levels capable of increasing cancer risk. The asserted injuries most commonly included bladder, gastric (stomach), pancreatic, esophageal, liver, and colorectal cancers, although the specific cancers evaluated varied by jurisdiction and procedural posture. From a legal standpoint, the litigation became a focal point for evaluating product ingredient toxicity theories, pharmaceutical stability allegations, and the evidentiary standards governing toxicology-based general causation under Daubert-style gatekeeping frameworks.
Although many claims did not survive general causation challenges, the litigation remains significant for its detailed judicial treatment of toxicological proof, expert methodology, and the limits of regulatory action in establishing civil liability.
In 2019, independent laboratory testing reported that ranitidine could form NDMA under certain conditions, including storage over time and exposure to elevated temperatures. These findings raised questions regarding the inherent chemical stability of the ranitidine molecule and prompted regulatory scrutiny in the United States and internationally. From a litigation perspective, the testing framed the dispute as involving potential degradation of an active pharmaceutical ingredient rather than isolated manufacturing contamination.
During this period, the U.S. Food and Drug Administration publicly acknowledged the testing data and initiated its own evaluation of NDMA levels in ranitidine products, setting the stage for subsequent regulatory and civil developments.
In April 2020, the FDA requested the withdrawal of all prescription and over-the-counter ranitidine products from the U.S. market. The agency cited data indicating that NDMA levels in some ranitidine products could increase over time and potentially exceed acceptable daily intake limits under certain storage conditions.
The FDA emphasized that its action was precautionary and did not include findings regarding cancer causation. Nonetheless, the withdrawal influenced subsequent civil litigation by reinforcing concerns related to product chemistry, pharmaceutical stability, and potential toxicological risk.
Following the FDA’s withdrawal request, thousands of personal injury lawsuits were filed nationwide. Federal cases were centralized into multidistrict litigation in the Southern District of Florida, where the court coordinated pretrial proceedings and addressed common scientific and evidentiary issues. Parallel proceedings advanced in multiple state courts, with plaintiffs asserting toxic tort theories centered on ranitidine’s alleged chemical instability, NDMA exposure pathways, and claimed links to cancer development. Across jurisdictions, toxicology, pharmacology, chemistry, and epidemiology became central to the evidentiary record, with general causation emerging as a threshold issue.
In late 2022, the federal MDL court excluded plaintiffs’ general causation expert testimony under Daubert. The court concluded that the proposed methodologies failed to reliably connect laboratory testing, regulatory thresholds, and epidemiological data to real-world human exposure capable of causing cancer.
Summary judgment was entered in favor of defendants for the designated cancer claims addressed by the court. The rulings focused on evidentiary sufficiency and did not purport to resolve causation for every cancer type alleged across all jurisdictions.
In September 2022, a large volume of ranitidine cases was filed in Delaware Superior Court. Plaintiffs designated ten general causation experts across multiple cancer types, while defendants designated a single general causation expert.
In May 2024, the Delaware Superior Court denied defendants’ motions to exclude plaintiffs’ experts under Rule 702. In July 2025, the Delaware Supreme Court reversed, concluding that plaintiffs’ general causation evidence failed to provide a scientifically reliable bridge between NDMA hazard data, laboratory testing, and ranitidine-specific human exposure. The matter was remanded for proceedings consistent with exclusion of general causation testimony.
Despite adverse general causation rulings, a number of state-court claims were resolved through negotiated settlements beginning in 2024. Several manufacturers announced settlement frameworks resolving substantial volumes of claims without admissions of liability.
These resolutions reflected litigation risk management, jurisdictional uncertainty, and cost considerations rather than judicial findings establishing scientific causation.
Plaintiffs’ Toxicology and Chemical Risk Assessment Expert Witnesses
Plaintiffs designated toxicology experts, including Charles William Jameson, Ph.D. and William Sawyer, Ph.D., to address NDMA carcinogenicity, dose–response principles, and exposure risk. Courts scrutinized the assumptions used to extrapolate laboratory findings to real-world pharmaceutical use.
Plaintiffs’ Epidemiology and Population-Level Causation Expert Witnesses
Epidemiology experts such as Alfred I. Neugut, M.D., Ph.D. and Bruce J. Trock, Ph.D., M.P.H. evaluated population-based data for statistical associations between ranitidine use and cancer outcomes. Judicial review focused on confounding, exposure misclassification, latency, and consistency across studies.
Plaintiffs’ Clinical Medicine and Oncology Expert Witnesses
Clinical and oncology experts, including Vinod K. Rustgi, M.D., MBA; Ioannis Hatzaras, M.D., MPH, Ph.D.; Dan J. Raz, M.D.; George Miller, M.D.; Pablo Leone, M.D.; and Vitaly Margulis, M.D., addressed cancer biology and disease mechanisms. Courts noted that such opinions depended on admissible general causation evidence.
Plaintiffs’ Regulatory and Risk Assessment Expert Witnesses
Regulatory testimony addressed FDA guidance on nitrosamines and acceptable daily intake limits. Courts treated this evidence as contextual background rather than independent proof of defect or causation.
Defendants’ General Causation Expert Witnesses
Defendants designated William C. Zamboni, Pharm.D., Ph.D., who challenged plaintiffs’ exposure assumptions and the connection between laboratory NDMA findings and real-world ranitidine use.
Distinguishing Hazard Identification from Legal Causation
Courts emphasized that identifying a chemical hazard does not establish legal causation without evidence of exposure at disease-causing levels.
Methodological Scrutiny of Toxicological Evidence
Judicial review focused on whether expert methodologies reliably connected laboratory data, regulatory thresholds, and epidemiological evidence to real-world human exposure.
Limits of Regulatory Action in Establishing Civil Liability
Regulatory actions, including FDA withdrawal requests, were treated as precautionary risk-management measures rather than determinations of product defect or causation.
Evaluation of Product Instability and Degradation Theories
Courts required product-specific, dose-specific, and use-condition-specific analysis rather than generalized chemical instability theories.
Case-Dispositive Impact of Early Expert Admissibility Rulings
Daubert-style rulings frequently determined outcomes before trial, underscoring the strategic importance of early expert challenges.
The ranitidine NDMA litigation highlights the central role of toxicology and expert reliability in pharmaceutical product liability cases. While many claims did not survive evidentiary scrutiny, the litigation provides a detailed framework for evaluating chemical exposure allegations, carcinogenic risk theories, and product ingredient toxicity claims.
Was the Zantac litigation considered a toxic tort?
Yes. The claims were based on alleged exposure to a carcinogenic chemical formed from a pharmaceutical product’s active ingredient.
Did the cases fail because no experts were retained?
No. Plaintiffs retained multiple experts, but courts excluded many opinions due to methodological deficiencies.
Did FDA withdrawal establish liability?
No. Courts treated FDA actions as regulatory risk-management decisions rather than proof of civil liability.
Why did some cases settle despite adverse rulings?
Settlements reflected litigation risk, costs, and jurisdictional uncertainty rather than uniform findings on causation.
Did the Zantac MDL rulings apply to all state-court cases nationwide?
No. The federal MDL rulings applied to cases within the MDL and addressed the admissibility of general causation evidence under federal evidentiary standards. State courts retained authority to apply their own evidentiary rules, which resulted in differing procedural outcomes across jurisdictions until later appellate review aligned some state rulings with the federal approach.
Plaintiffs’ Toxicology and Chemical Risk Assessment Expert Witnesses
Plaintiffs designated toxicology experts, including Charles William Jameson, Ph.D. and William Sawyer, Ph.D., to address NDMA carcinogenicity, dose–response principles, and exposure risk. Courts scrutinized the assumptions used to extrapolate laboratory findings to real-world pharmaceutical use.
Plaintiffs’ Epidemiology and Population-Level Causation Expert Witnesses
Epidemiology experts such as Alfred I. Neugut, M.D., Ph.D. and Bruce J. Trock, Ph.D., M.P.H. evaluated population-based data for statistical associations between ranitidine use and cancer outcomes. Judicial review focused on confounding, exposure misclassification, latency, and consistency across studies.
Plaintiffs’ Clinical Medicine and Oncology Expert Witnesses
Clinical and oncology experts, including Vinod K. Rustgi, M.D., MBA; Ioannis Hatzaras, M.D., MPH, Ph.D.; Dan J. Raz, M.D.; George Miller, M.D.; Pablo Leone, M.D.; and Vitaly Margulis, M.D., addressed cancer biology and disease mechanisms. Courts noted that such opinions depended on admissible general causation evidence.
Plaintiffs’ Regulatory and Risk Assessment Expert Witnesses
Regulatory testimony addressed FDA guidance on nitrosamines and acceptable daily intake limits. Courts treated this evidence as contextual background rather than independent proof of defect or causation.
Defendants’ General Causation Expert Witnesses
Defendants designated William C. Zamboni, Pharm.D., Ph.D., who challenged plaintiffs’ exposure assumptions and the connection between laboratory NDMA findings and real-world ranitidine use.
Distinguishing Hazard Identification from Legal Causation
Courts emphasized that identifying a chemical hazard does not establish legal causation without evidence of exposure at disease-causing levels.
Methodological Scrutiny of Toxicological Evidence
Judicial review focused on whether expert methodologies reliably connected laboratory data, regulatory thresholds, and epidemiological evidence to real-world human exposure.
Limits of Regulatory Action in Establishing Civil Liability
Regulatory actions, including FDA withdrawal requests, were treated as precautionary risk-management measures rather than determinations of product defect or causation.
Evaluation of Product Instability and Degradation Theories
Courts required product-specific, dose-specific, and use-condition-specific analysis rather than generalized chemical instability theories.
Case-Dispositive Impact of Early Expert Admissibility Rulings
Daubert-style rulings frequently determined outcomes before trial, underscoring the strategic importance of early expert challenges.
The ranitidine NDMA litigation highlights the central role of toxicology and expert reliability in pharmaceutical product liability cases. While many claims did not survive evidentiary scrutiny, the litigation provides a detailed framework for evaluating chemical exposure allegations, carcinogenic risk theories, and product ingredient toxicity claims.
Was the Zantac litigation considered a toxic tort?
Yes. The claims were based on alleged exposure to a carcinogenic chemical formed from a pharmaceutical product’s active ingredient.
Did the cases fail because no experts were retained?
No. Plaintiffs retained multiple experts, but courts excluded many opinions due to methodological deficiencies.
Did FDA withdrawal establish liability?
No. Courts treated FDA actions as regulatory risk-management decisions rather than proof of civil liability.
Why did some cases settle despite adverse rulings?
Settlements reflected litigation risk, costs, and jurisdictional uncertainty rather than uniform findings on causation.
Did the Zantac MDL rulings apply to all state-court cases nationwide?
No. The federal MDL rulings applied to cases within the MDL and addressed the admissibility of general causation evidence under federal evidentiary standards. State courts retained authority to apply their own evidentiary rules, which resulted in differing procedural outcomes across jurisdictions until later appellate review aligned some state rulings with the federal approach.
Pharmaceutical Product Liability
Carcinogenesis
Chemical Exposures
Chemical Analysis
Drug Regulation
FDA Regulation
Risk Assessment
Product Safety
Pharmaceutical, +4
Pharmaceutical
Securities, +4
Pharmaceutical